Long-lasting recombinant factor VIII proteins for hemophilia A

Larsson, 1985, Life expectancy of Swedish haemophiliacs, 1831-1980, Br J Haematol, 59, 593, 10.1111/j.1365-2141.1985.tb07353.x

Plug, 2006, Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study, J Thromb Haemost, 4, 510, 10.1111/j.1538-7836.2006.01808.x

Darby, 2007, Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, Blood, 110, 815, 10.1182/blood-2006-10-050435

Kingdon, 2002, An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy, Biotechnol Appl Biochem, 35, 141, 10.1042/BA20010082

Srivastava, 2013, Guidelines for the management of hemophilia, Haemophilia, 19, e1, 10.1111/j.1365-2516.2012.02909.x

Berntorp, 2012, Modern haemophilia care, Lancet, 379, 1447, 10.1016/S0140-6736(11)61139-2

Simpson, 2012, Management of joint bleeding in hemophilia, Expert Rev Hematol, 5, 459, 10.1586/ehm.12.27

Kauvar, 2006, Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations, J Trauma, 60, S3, 10.1097/01.ta.0000199961.02677.19

Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 357, 535, 10.1056/NEJMoa067659

Ahnström, 2004, A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, 10, 689, 10.1111/j.1365-2516.2004.01036.x

Collins, 2010, Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, J Thromb Haemost, 8, 269, 10.1111/j.1538-7836.2009.03703.x

Ewenstein, 2004, Consensus recommendations for use of central venous access devices in haemophilia, Haemophilia, 10, 629, 10.1111/j.1365-2516.2004.00943.x

Thornburg, 2009, Prophylactic factor infusions for patients with hemophilia: challenges with treatment adherence, JCD, 1

Schrijvers, 2013, Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review, Haemophilia, 19, 355, 10.1111/hae.12079

Aledort, 1994, A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group, J Intern Med, 236, 391, 10.1111/j.1365-2796.1994.tb00815.x

Tagliaferri, 2008, Effects of secondary prophylaxis started in adolescent and adult haemophiliacs, Haemophilia, 14, 945, 10.1111/j.1365-2516.2008.01791.x

World Federation of Hemophilia Diagnosis and management of inhibitors to factors VIII and IX: an introductory discussion for physicians Accessed May 30, 2013 Available from: http://www1.wfh.org/publication/files/pdf-1178.pdf

Kempton, 2012, Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A, Am J Hematol, 87, 933, 10.1002/ajh.23269

Gouw, 2007, Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, 109, 4648, 10.1182/blood-2006-11-056291

Powell, 2007, Liposomal approach towards the development of a longer-acting factor VIII, Haemophilia, 13, 23, 10.1111/j.1365-2516.2007.01502.x

Kaufman, 1998, Can we improve on nature? “Super molecules” of factor VIII, Haemophilia, 4, 370, 10.1046/j.1365-2516.1998.440370.x

Gale, 2003, An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa, J Thromb Haemost, 1, 1966, 10.1046/j.1538-7836.2003.00348.x

Gale, 2006, Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants, J Thromb Haemost, 4, 1315, 10.1111/j.1538-7836.2006.01951.x

Ivens, 2013, PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers, Haemophilia, 19, 11, 10.1111/j.1365-2516.2012.02931.x

Mei, 2010, Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment, Blood, 116, 270, 10.1182/blood-2009-11-254755

Kaufman, 2013, Molecular approaches for improved clotting factors for hemophilia, Hematology Am Soc Hematol Educ Program, 2013, 30, 10.1182/asheducation-2013.1.30

Metzner, 2009, Genetic fusion to albumin improves the pharmacokinetic properties of factor IX, Thromb Haemost, 102, 634, 10.1160/TH09-04-0255

Peters, 2010, Prolonged activity of factor IX as a monomeric Fc fusion protein, Blood, 115, 2057, 10.1182/blood-2009-08-239665

Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155

Coyle, 2012, Abstract FP-MO-03.2-3: An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treatment patients with severe hemophilia A, Haemophilia, 18, 22

Turecek, 2012, BAX 855, a PEGylated rFVIII product with prolonged half-life: development, functional and structural characterisation, Hamostaseologie, 32, S29, 10.1055/s-0037-1619772

Tiede, 2013, Enhancing the pharmacokinetic properties of recombinant factor VIII: first in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A, J Thromb Haemost, 11, 670, 10.1111/jth.12161

Thim, 2010, Purification and characterization of a new recombinant factor VIII (N8), Haemophilia, 16, 349, 10.1111/j.1365-2516.2009.02135.x

Powell, 2012, Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients, Blood, 119, 3031, 10.1182/blood-2011-09-382846

Agerso, 2012, Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs, Haemophilia, 18, 941, 10.1111/j.1365-2516.2012.02896.x

Martinowitz, 2011, Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A, Haemophilia, 17, 854, 10.1111/j.1365-2516.2011.02495.x

Peters, 2013, Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein, J Thromb Haemost, 11, 132, 10.1111/jth.12076

Dumont, 2012, Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs, Blood, 119, 3024, 10.1182/blood-2011-08-367813

Durocher, 2009, Expression systems for therapeutic glycoprotein production, Curr Opin Biotechnol, 20, 700, 10.1016/j.copbio.2009.10.008

Walsh, 2010, Post-translational modifications of protein biopharmaceuticals, Drug Discov Today, 15, 773, 10.1016/j.drudis.2010.06.009

Swiech, 2012, Human cells: new platform for recombinant therapeutic protein production, Protein Expr Purif, 84, 147, 10.1016/j.pep.2012.04.023

Zhang, 2012, Enzymatic release and detection of galactose-alpha-1,3-galactose (a-Gal) in recombinant FVIII products, Haemophilia, 18, PO

Ghaderi, 2012, Production platforms for biotherapeutic glycoproteins. occurence, impact, and challenges of non-human sialylation, Biotechnol Genet Eng Rev, 28, 147, 10.5661/bger-28-147

Lenting, 2007, Clearance mechanisms of von Willebrand factor and factor VIII, J Thromb Haemost, 5, 1353, 10.1111/j.1538-7836.2007.02572.x

Suiter, 2010, Recombinant human von Willebrand factor (rVWF): First-in-human study evaluating pharmacokinetics, demonstrating safety and tolerability in type 3 von Willebrand disease [abstract], Blood (ASH Annual Meeting Abstracts), 116, 237

Bjorkman, 2012, Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight, Blood, 119, 612, 10.1182/blood-2011-07-360594

Ljung, 2013, Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients, Haemophilia, 19, 481, 10.1111/hae.12094

Lindvall, 2012, Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy, Haemophilia, 18, 855, 10.1111/j.1365-2516.2012.02879.x

Lencer, 2005, A passionate kiss, then run: exocytosis and recycling of IgG by FcRn, Trends Cell Biol, 15, 5, 10.1016/j.tcb.2004.11.004

Ghetie, 2000, Multiple roles for the major histocompatibility complex class I- related receptor FcRn, Annu Rev Immunol, 18, 739, 10.1146/annurev.immunol.18.1.739

McGarry, 1983, Intracellular distribution and degradation of immunoglobulin G and immunoglobulin G fragments injected into HeLa cells, J Cell Biol, 96, 338, 10.1083/jcb.96.2.338

Israel, 1997, Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells, Immunology, 92, 69, 10.1046/j.1365-2567.1997.00326.x